NEW YORK, Jan. 7, 2022 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-derived therapies, announces the resignation of Stephen Hurst from his role as a Director of the Company’s Board of Directors. “On behalf of MindMed, the Board of Directors, and the Executive team, I thank Steve for his significant…


Previous articlePsychedelic Bulletin: Big Pharma’s Foray Into Psychedelics; Psilocybin Trial Makes Headlines; Bill to Legalize Psilocybin in Washington State Filed
Next articleMydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds